Summary

Report Scope
This report provides an overview of the global vaccine adjuvants market. It includes global revenue ($ millions), with 2025 as the base year, estimates for 2026, and forecasts through 2031. The market is segmented by product type, disease type, vaccine type, route of administration, application, and region. Based on product type, vaccine adjuvants are categorized into particulate-based adjuvants, emulsion adjuvants, saponin-based adjuvants, Toll-like receptor (TLR) agonists, and other adjuvants. Based on disease type, the market is categorized into infectious diseases, cancer, and other diseases. The regions covered in this study include North America, Europe, Asia-Pacific, South America, and the Middle East and Africa, with a focus on major countries in each region.
The report highlights the key trends and challenges affecting the market, along with analysis and discussions regarding patents, clinical trials, and emerging technologies.
The report concludes with an analysis of the competitive landscape, which provides rankings and market shares for key companies in the global vaccine adjuvants market. A dedicated company profile section provides information on leading companies, including GSK Plc., CSL, Novavax, Croda International Plc., Dynavax Technologies Corp., Avanti Research, Desert King, InvivoGen, SEPPIC, and SPI Pharma.
Report Includes
- An analysis of the global markets for vaccine adjuvant compounds and systems used in human and veterinary vaccines production
- Analyses of the global market trends, with historic data from 2023 to 2025, estimates for 2026 and projections of CAGRs through 2031
- Estimates of the market size and revenue prospects for global market, accompanied by a market share analysis by product type, disease type, vaccine type, route of administration, application, and region
- Facts and figures pertaining to the market dynamics, recent technological advancements in diabetes management, regulations, prospects and the impact of macroeconomic variables
- Insights derived from Porter’s Five Forces model, as well as global supply chain analyses
- Review of emerging technologies, market applications, industry structure, and key initiatives in clinical sequencing
- Patent review, featuring key granted and published patents
- Analysis of the industry structure, including companies’ market shares and rankings, product mappings, strategic initiatives, M&A activity and a venture funding outlook
- Overview of sustainability trends and ESG developments, with emphasis on consumer attitudes, as well as the ESG risk ratings and practices of leading companies
- Profiles of the leading global companies

ページTOPに戻る

Table of Contents

Table of Contents
Chapter 1 Executive Summary
Market Outlook
Scope of the Report
Market Summary
Market Dynamics and Growth Factors
Emerging Technologies
Segmental Analysis
Regional Analysis
Conclusion
Chapter 2 Market Overview
Market Definition
Different Categories of Vaccine Adjuvants
Role of Adjuvants in Different Vaccine Types
Future of Vaccine Adjuvants
Porter's Five Forces Analysis
Threat of New Entrants (Low)
Bargaining Power of Buyers (High)
Bargaining Power of Suppliers (Moderate)
Threat of Substitutes (Low)
Level of Competitiveness (Moderate)
Macroeconomic Factors Analysis
Economic Growth and Healthcare Spending
Rising Prevalence of Infectious and Chronic Diseases
Regulatory Factors
Technological Developments
Impact of U.S. Tariff Laws on the Vaccine Adjuvants Market
Chapter 3 Market Dynamics
Market Dynamics
Market Drivers
Essential Role of Adjuvants in Modern Vaccine Platforms
Expansion of Global Immunization Programs and Vaccine Coverage
Rising Veterinary Vaccination and Livestock Disease-Control Needs
Technological Developments in Next-Generation Adjuvants
Market Restraints
High Regulatory and Clinical Validation Requirements
Side Effects and Toxicity of Adjuvants
Supply Chain Constraints for Specialized Adjuvant Components
Market Opportunities
Development of Advanced Combination and Precision Adjuvant Systems
Expansion of Therapeutic and Cancer Vaccine Development
Growth in the Companion Animal Market
Chapter 4 Regulatory Landscape
Overview
Regulations and Standards by Select Country or Region
Chapter 5 Emerging Technologies and Patent Analysis
Overview
Emerging Technologies
Development of Precision Combination Adjuvant Systems
Scalable and Synthetic Production of Advanced Adjuvants
Nanostructured and Lipid-Based Delivery Platforms with Integrated Immunostimulation
Clinical Trial Analysis
Key Takeaways
Clinical Trials Analysis by Type of Study
Clinical Trials Analysis by Status
Clinical Trials Analysis by Phase
Patent Analysis
Key Takeaways
Patents, by Year
By Top Applicant
By Top Owner
By Jurisdiction
Chapter 6 Market Segmentation Analysis
Segmentation Breakdown
Vaccine Adjuvants Market, by Product Type
Key Takeaways
Particulate-Based Adjuvants
Emulsion Adjuvants
Saponin-Based Adjuvants
TLR Agonists
Other Adjuvants
Vaccine Adjuvants Market, by Disease Type
Key Takeaways
Infectious Diseases
Cancer
Other Diseases
Vaccine Adjuvants Market, by Vaccine Type
Key Takeaways
Human Vaccines
Veterinary Vaccines
Vaccine Adjuvants Market, by Application
Key Takeaways
Commercial Applications
Research Applications
Vaccine Adjuvants Market, by Route of Administration
Key Takeaways
Intramuscular
Subcutaneous
Intradermal
Other Routes of Administration
Geographic Breakdown
Vaccine Adjuvants Market, by Region
Key Takeaways
North America
Europe
Asia-Pacific
South America
Middle East and Africa
Chapter 7 Competitive Intelligence
Key Takeaways
Competitive Landscape
Global Market Shares of Leading Companies
Strategic Analysis
Chapter 8 Appendix
Research Methodology
References
Abbreviations
Company Profiles
AVANTI RESEARCH
CRODA INTERNATIONAL PLC
CSL
DESERT KING
DYNAVAX TECHNOLOGIES CORP.
GSK PLC
INVIVOGEN
NOVAVAX
SEPPIC
SPI PHARMA
A Few Emerging Start-ups/Market Disruptors

ページTOPに戻る

List of Tables/Graphs

List of Tables
Summary Table : Global Market for Vaccine Adjuvants, by Region, Through 2031
Table 1 : Key Limitations of Traditional Vaccine Adjuvants
Table 2 : Advantages of Next-Generation Vaccine Adjuvants
Table 3 : Categories of Vaccine Adjuvants and Their Mechanisms
Table 4 : Role of Adjuvants in Different Vaccine Types
Table 5 : Porter’s Five Forces: Rating Scale
Table 6 : U.S. Pet Ownership Statistics, Dogs and Cats, 2025
Table 7 : Regulatory Landscape Governing Vaccine Adjuvants, by Country/Region
Table 8 : Clinical Trials for Vaccine Adjuvants, by Type of Study, as of March 2026
Table 9 : Clinical Trials for Vaccine Adjuvants, by Status, as of March 2026
Table 10 : Clinical Trials for Vaccine Adjuvants, by Phase, as of March 2026
Table 11 : Notable Patents, by Top Applicants, 2024–2025
Table 12 : Patents, by Top Owner, 2024–2025
Table 13 : Patents, by Jurisdiction, 2024–2025
Table 14 : Global Market for Vaccine Adjuvants, by Product Type, Through 2031
Table 15 : Global Vaccine Adjuvants Market for Particulate-Based Adjuvants, by Region, Through 2031
Table 16 : Global Vaccine Adjuvants Market for Emulsion Adjuvants, by Region, Through 2031
Table 17 : Global Vaccine Adjuvants Market for Saponin-Based Adjuvants, by Region, Through 2031
Table 18 : Global Vaccine Adjuvants Market for TLR Agonists, by Region, Through 2031
Table 19 : Global Vaccine Adjuvants Market for Other Adjuvants, by Region, Through 2031
Table 20 : Global Market for Vaccine Adjuvants, by Disease Type, Through 2031
Table 21 : Global Vaccine Adjuvants Market for Infectious Diseases, by Region, Through 2031
Table 22 : Global Vaccine Adjuvants Market for Cancer, by Region, Through 2031
Table 23 : Global Vaccine Adjuvants Market for Other Diseases, by Region, Through 2031
Table 24 : Global Market for Vaccine Adjuvants, by Vaccine Type, Through 2031
Table 25 : Global Vaccine Adjuvants Market for Human Vaccines, by Region, Through 2031
Table 26 : Global Vaccine Adjuvants Market for Veterinary Vaccines, by Region, Through 2031
Table 27 : Global Market for Vaccine Adjuvants, by Application, Through 2031
Table 28 : Global Vaccine Adjuvants Market for Commercial Applications, by Region, Through 2031
Table 29 : Global Vaccine Adjuvants Market for Research Applications, by Region, Through 2031
Table 30 : Global Market for Vaccine Adjuvants, by Route of Administration, Through 2031
Table 31 : Global Vaccine Adjuvants Market for Intramuscular Route of Administration, by Region, Through 2031
Table 32 : Global Vaccine Adjuvants Market for Subcutaneous Route of Administration, by Region, Through 2031
Table 33 : Global Vaccine Adjuvants Market for Intradermal Route of Administration, by Region, Through 2031
Table 34 : Global Vaccine Adjuvants Market for Other Routes of Administration, by Region, Through 2031
Table 35 : Global Market for Vaccine Adjuvants, by Region, Through 2031
Table 36 : North American Market for Vaccine Adjuvants, by Country, Through 2031
Table 37 : North American Market for Vaccine Adjuvants, by Product Type, Through 2031
Table 38 : North American Market for Vaccine Adjuvants, by Disease Type, Through 2031
Table 39 : North American Market for Vaccine Adjuvants, by Vaccine Type, Through 2031
Table 40 : North American Market for Vaccine Adjuvants, by Route of Administration, Through 2031
Table 41 : North American Market for Vaccine Adjuvants, by Application, Through 2031
Table 42 : European Market for Vaccine Adjuvants, by Country, Through 2031
Table 43 : European Market for Vaccine Adjuvants, by Product Type, Through 2031
Table 44 : European Market for Vaccine Adjuvants, by Disease Type, Through 2031
Table 45 : European Market for Vaccine Adjuvants, by Vaccine Type, Through 2031
Table 46 : European Market for Vaccine Adjuvants, by Route of Administration, Through 2031
Table 47 : European Market for Vaccine Adjuvants, by Application, Through 2031
Table 48 : Asia-Pacific Market for Vaccine Adjuvants, by Country, Through 2031
Table 49 : Asia-Pacific Market for Vaccine Adjuvants, by Product Type, Through 2031
Table 50 : Asia-Pacific Market for Vaccine Adjuvants, by Disease Type, Through 2031
Table 51 : Asia-Pacific Market for Vaccine Adjuvants, by Vaccine Type, Through 2031
Table 52 : Asia-Pacific Market for Vaccine Adjuvants, by Route of Administration, Through 2031
Table 53 : Asia-Pacific Market for Vaccine Adjuvants, by Application, Through 2031
Table 54 : South American Market for Vaccine Adjuvants, by Country, Through 2031
Table 55 : South American Market for Vaccine Adjuvants, by Product Type, Through 2031
Table 56 : South American Market for Vaccine Adjuvants, by Disease Type, Through 2031
Table 57 : South American Market for Vaccine Adjuvants, by Vaccine Type, Through 2031
Table 58 : South American Market for Vaccine Adjuvants, by Route of Administration, Through 2031
Table 59 : South American Market for Vaccine Adjuvants, by Application, Through 2031
Table 60 : MEA Market for Vaccine Adjuvants, by Sub-region, Through 2031
Table 61 : MEA Market for Vaccine Adjuvants, by Product Type, Through 2031
Table 62 : MEA Market for Vaccine Adjuvants, by Disease Type, Through 2031
Table 63 : MEA Market for Vaccine Adjuvants, by Vaccine Type, Through 2031
Table 64 : MEA Market for Vaccine Adjuvants, by Route of Administration, Through 2031
Table 65 : MEA Market for Vaccine Adjuvants, by Application, Through 2031
Table 66 : Leading Providers of Vaccine Adjuvants, 2025
Table 67 : Recent Developments in the Vaccine Adjuvants Market, January 2023–March 2026
Table 68 : Abbreviations Used in the Report
Table 69 : Avanti Research: Company Snapshot
Table 70 : Avanti Research: Product Portfolio
Table 71 : Avanti Research: News/Key Developments, 2025
Table 72 : Croda International Plc: Company Snapshot
Table 73 : Croda International Plc: Financial Performance, FY 2024 and 2025
Table 74 : Croda International Plc: Product Portfolio
Table 75 : Croda International Plc: News/Key Developments, 2023-2024
Table 76 : CSL.: Company Snapshot
Table 77 : CSL: Financial Performance, FY 2023 and 2024
Table 78 : CSL: Product Portfolio
Table 79 : CSL: News/Key Developments, 2024
Table 80 : Desert King: Company Snapshot
Table 81 : Desert King: Product Portfolio
Table 82 : Desert King: News/Key Developments, 2025
Table 83 : Dynavax Technologies Corp.: Company Snapshot
Table 84 : Dynavax Technologies Corp.: Product Portfolio
Table 85 : Dynavax Technologies Corp.: News/Key Developments, 2023-2026
Table 86 : GSK plc: Company Snapshot
Table 87 : GSK plc: Financial Performance, FY 2024 and 2025
Table 88 : GSK plc: Product Portfolio
Table 89 : GSK plc: News/Key Developments, 2023-2025
Table 90 : InvivoGen: Company Snapshot
Table 91 : InvivoGen: Product Portfolio
Table 92 : InvivoGen: News/Key Developments, 2024
Table 93 : Novavax: Company Snapshot
Table 94 : Novavax: Financial Performance, FY 2024 and 2025
Table 95 : Novavax: Product Portfolio
Table 96 : Novavax: News/Key Developments, 2024-2026
Table 97 : SEPPIC: Company Snapshot
Table 98 : SEPPIC: Product Portfolio
Table 99 : SEPPIC: News/Key Developments, 2025
Table 100 : SPI PHARMA: Company Snapshot
Table 101 : SPI PHARMA: Product Portfolio
Table 102 : SPI PHARMA: News/Key Developments, 2024
Table 103 : List of a Few Emerging Startups/Market Disruptors

List of Figures
Summary Figure : Summary Figure: Global Market Shares for Vaccine Adjuvants, by Region, 2025
Figure 1 : Porter’s Five Forces Analysis: Vaccine Adjuvants Market
Figure 2 : Market Dynamics of Vaccine Adjuvants
Figure 3 : Emerging Technologies in the Vaccine Adjuvants Market
Figure 4 : Patents Granted, by Year, 2024–2025
Figure 5 : Global Market Shares for Vaccine Adjuvants, by Product Type, 2025
Figure 6 : Global Vaccine Adjuvants Market Shares for Particulate-Based Adjuvants, by Region, 2025
Figure 7 : Global Vaccine Adjuvants Market Shares for Emulsion Adjuvants, by Region, 2025
Figure 8 : Global Vaccine Adjuvants Market Shares for Saponin-Based Adjuvants, by Region, 2025
Figure 9 : Global Vaccine Adjuvants Market Shares for TLR Agonists, by Region, 2025
Figure 10 : Global Vaccine Adjuvants Market Shares for Other Adjuvants, by Region, 2025
Figure 11 : Global Market Shares for Vaccine Adjuvants, by Disease Type, 2025
Figure 12 : Global Vaccine Adjuvants Market Shares for Infectious Diseases, by Region, 2025
Figure 13 : Global Vaccine Adjuvants Market Shares for Cancer, by Region, 2025
Figure 14 : Global Vaccine Adjuvants Market Shares for Other Diseases, by Region, 2025
Figure 15 : Global Market Shares for Vaccine Adjuvants, by Vaccine Type, 2025
Figure 16 : Global Vaccine Adjuvants Market Shares for Human Vaccines, by Region, 2025
Figure 17 : Global Vaccine Adjuvants Market Shares for Veterinary Vaccines, by Region, 2025
Figure 18 : Global Market Shares for Vaccine Adjuvants, by Application, 2025
Figure 19 : Global Vaccine Adjuvants Market Shares for Commercial Applications, by Region, 2025
Figure 20 : Global Vaccine Adjuvants Market Shares for Research Applications, by Region, 2025
Figure 21 : Global Market Shares for Vaccine Adjuvants, by Route of Administration, 2025
Figure 22 : Global Vaccine Adjuvants Market Shares for Intramuscular Route of Administration, by Region, 2025
Figure 23 : Global Vaccine Adjuvants Market Shares for Subcutaneous Route of Administration, by Region, 2025
Figure 24 : Global Vaccine Adjuvants Market Shares for Intradermal Route of Administration, by Region, 2025
Figure 25 : Global Vaccine Adjuvants Market Shares for Other Routes of Administration, by Region, 2025
Figure 26 : Global Market Shares for Vaccine Adjuvants, by Region, 2025
Figure 27 : North American Market Shares for Vaccine Adjuvants, by Country, 2025
Figure 28 : European Market Shares for Vaccine Adjuvants, by Country, 2025
Figure 29 : Asia-Pacific Market Shares for Vaccine Adjuvants, by Country, 2025
Figure 30 : South American Market Shares for Vaccine Adjuvants, by Country, 2025
Figure 31 : MEA Market Shares for Vaccine Adjuvants, by Sub-region, 2025
Figure 32 : Global Market Share Analysis for Vaccine Adjuvants, by Company, 2025
Figure 33 : Croda International Plc: Revenue Shares, by Business Unit, FY 2025
Figure 34 : Croda International Plc: Revenue Shares, by Region/Country, FY 2025
Figure 35 : CSL: Revenue Shares, by Business Unit, FY 2024
Figure 36 : CSL: Revenue Shares, by Region/Country, FY 2024
Figure 37 : GSK plc: Revenue Shares, by Business Unit, FY 2025
Figure 38 : GSK Plc: Revenue Shares, by Region/Country, FY 2025
Figure 39 : Novavax: Revenue Shares, by Business Unit, FY 2025
Figure 40 : Novavax: Revenue Shares, by Region/Country, FY 2025